Porvair Sciences new medium and high bind Krystal microplates set a new standard for uniform and reproducible capture of a wide range of biomolecules ready for affinity binding assays such as ELISA's.

Antlia Bioscience, Inc., and XL-protein GmbH are pleased to announce a strategic slliance using XL-protein's proprietary PASylation® technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure.

BioChromato Inc. has published a technical poster that studies how its unique vacuum-assisted vortex concentration (VVC) technology offers significant benefits in achieving rapid concentration of samples dissolved in high boiling point solvents.

BioChromato Inc. reports that the pharmacokinetics department at a leading Japanese pharmaceutical company has found that RAPID Slit Seals offer significant benefits compared to conventional silicone mats for maintaining the integrity of microplate samples.

BioChromato Inc. reports how the Department of Bioimaging Information Analysis at Gunma University (Japan) is benefiting from the ability of its Smart Evaporator C1 to safely and efficiently concentrate low volume samples.

LabVantage Solutions, Inc., today announced the United States Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a contract to supply its LabVantage Pharma laboratory information management system (LIMS) to the Walter Reed Army Institute of Research (WRAIR).

Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has granted a positive opinion for an Orphan Drug Designation (ODD) status to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.

Iksuda Therapeutics (Iksuda), today announces it has executed its option to secure exclusive, worldwide rights to develop a novel class of tumour-activated prodrug payloads from the University of Goettingen, following a successful collaboration exemplifying the series in ADC formats.

Impel NeuroPharma announced that it has presented patient-reported outcomes data from the Company’s pivotal Phase 3, open-label study “STOP 301” of INP104 (dihydroergotamine mesylate) or DHE using the company’s proprietary POD technology, for the treatment of acute migraine in an oral presentation at the Migraine Trust Virtual Symposium (MTIS) to be held from October 3-9, 2020.

CellGenix GmbH, announces the completion of the second phase of their facility expansion. By implementing an automated filling and freeze-drying line and increasing bulkware production footprint, finished product capacity for cytokines is substantially increased.